L S Schneider

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Galantamine for vascular dementia: some answers, some questions
    Lon S Schneider
    Department of Psychiatry and Neurology, Keck School of Medicine and Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90033, USA
    Lancet 359:1265-6. 2002
  2. pmc Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study
    Ling Zheng
    Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Am J Psychiatry 166:583-90. 2009
  3. pmc Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
  4. ncbi request reprint Does donepezil improve executive function in patients with CADASIL?
    Lon S Schneider
    Lancet Neurol 7:287-9. 2008
  5. ncbi request reprint Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease
    Robert A Rosenheck
    Northeast Program Evaluation Center 182, VA Connecticut Health Care System, West Haven, Connecticut 06516, USA
    Arch Gen Psychiatry 64:1259-68. 2007
  6. pmc Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Electronic address
    Alzheimers Dement 10:247-50. 2014
  7. doi request reprint Alzheimer disease pharmacologic treatment and treatment research
    Lon S Schneider
    Keck School of Medicine, University of Southern California, 1540 Alcazar St, CHP 216, Los Angeles, CA 90033, USA
    Continuum (Minneap Minn) 19:339-57. 2013
  8. ncbi request reprint Recruitment methods for United States Alzheimer disease prevention trials
    L S Schneider
    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Nutr Health Aging 16:331-5. 2012
  9. ncbi request reprint Cholinesterase inhibitors for vascular dementia?
    Lon S Schneider
    Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Lancet Neurol 2:658-9. 2003
  10. ncbi request reprint Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    JAMA 294:1934-43. 2005

Detail Information

Publications74

  1. ncbi request reprint Galantamine for vascular dementia: some answers, some questions
    Lon S Schneider
    Department of Psychiatry and Neurology, Keck School of Medicine and Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90033, USA
    Lancet 359:1265-6. 2002
  2. pmc Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study
    Ling Zheng
    Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Am J Psychiatry 166:583-90. 2009
    ..Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects...
  3. pmc Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
    ..The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior...
  4. ncbi request reprint Does donepezil improve executive function in patients with CADASIL?
    Lon S Schneider
    Lancet Neurol 7:287-9. 2008
  5. ncbi request reprint Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease
    Robert A Rosenheck
    Northeast Program Evaluation Center 182, VA Connecticut Health Care System, West Haven, Connecticut 06516, USA
    Arch Gen Psychiatry 64:1259-68. 2007
    ..Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD)...
  6. pmc Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Electronic address
    Alzheimers Dement 10:247-50. 2014
    ..The current draft guidelines may inadvertently constrain efforts to better assess the clinical effects of new drugs and inhibit innovation in an area where evidence-based clinical research practices are still evolving. ..
  7. doi request reprint Alzheimer disease pharmacologic treatment and treatment research
    Lon S Schneider
    Keck School of Medicine, University of Southern California, 1540 Alcazar St, CHP 216, Los Angeles, CA 90033, USA
    Continuum (Minneap Minn) 19:339-57. 2013
    ..Current experimental drug development, including challenges to developing successful drugs for Alzheimer disease, are also reviewed and assessed...
  8. ncbi request reprint Recruitment methods for United States Alzheimer disease prevention trials
    L S Schneider
    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Nutr Health Aging 16:331-5. 2012
    ..Improvements in recruitment methods can enhance the likelihood for accurately demonstrating the efficacy of an effective drug. Effective therapeutics to prevent AD await discovery and proof...
  9. ncbi request reprint Cholinesterase inhibitors for vascular dementia?
    Lon S Schneider
    Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Lancet Neurol 2:658-9. 2003
  10. ncbi request reprint Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    JAMA 294:1934-43. 2005
    ....
  11. pmc Current Alzheimer's disease clinical trials: methods and placebo outcomes
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences and Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Alzheimers Dement 5:388-97. 2009
    ..Yet, no 18-month trial has shown statistically significant outcomes favoring the test drug. We examined characteristics and underlying assumptions of these trials by assessing the placebo groups...
  12. pmc Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arch Neurol 68:58-66. 2011
    ..To assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride...
  13. pmc Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
    Lon S Schneider
    Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Alzheimers Dement 6:367-77. 2010
    ....
  14. ncbi request reprint Psychosis of Alzheimer's disease: clinical characteristics and history
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, University of Southern California, Keck School of Medicine, 1975 Zonal Avenue, KAM 400, Los Angeles, CA 90033, USA
    J Psychiatr Res 38:105-11. 2004
    ..There is some evidence that psychotic symptoms improve modestly with antipsychotic medication treatment. There is sufficient descriptive and empirical research to support the validity of a syndrome of psychosis of Alzheimer's disease...
  15. ncbi request reprint An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression
    Lon S Schneider
    Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, and the Leonard Davis School of Gerontology, University of SouthernCalifornia, Los Angeles, CA 90033, USA
    Am J Psychiatry 160:1277-85. 2003
    ..There have been few placebo-controlled trials of selective serotonin reuptake inhibitors for depressed elderly patients. This placebo-controlled study of sertraline was designed to confirm the results of non-placebo-controlled trials...
  16. ncbi request reprint AD2000: donepezil in Alzheimer's disease
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Lancet 363:2100-1. 2004
  17. ncbi request reprint Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA
    Schizophr Bull 29:57-72. 2003
    ....
  18. doi request reprint Prevention therapeutics of dementia
    Lon S Schneider
    Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Alzheimers Dement 4:S122-30. 2008
    ..This paper will address current barriers to developing drugs for AD, and offer new considerations for accelerating drug discovery, development, and clinical trials...
  19. ncbi request reprint Lack of evidence for the efficacy of memantine in mild Alzheimer disease
    Lon S Schneider
    University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Arch Neurol 68:991-8. 2011
    ..Yet memantine is very frequently prescribed for mild AD and mild cognitive impairment, and a manufacturer-sponsored meta-analysis claimed its efficacy in mild AD...
  20. ncbi request reprint Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment
    Lon S Schneider
    University of Southern California, Keck School of Medicine, Los Angeles, California, USA
    Alzheimer Dis Assoc Disord 19:279-83. 2005
    ....
  21. ncbi request reprint National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology
    L S Schneider
    Clinical Antipsychotic Trials of Intervention Effectiveness Program of the National Institute of Mental Health at the University of North Carolina, Chapel Hill, NC, USA
    Am J Geriatr Psychiatry 9:346-60. 2001
    ..They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented...
  22. ncbi request reprint ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Alzheimer Dis Assoc Disord 20:S124-38. 2006
    ..An important consideration was whether global assessments are specific and sensitive measures of change during a prevention trial...
  23. ncbi request reprint Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...
  24. pmc The potential and limits for clinical trials for early Alzheimer's disease and some recommendations
    L S Schneider
    University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    J Nutr Health Aging 14:295-8. 2010
    ..Models and simulations using existing clinical trials databases would be helpful in planning early AD trials...
  25. ncbi request reprint Treatment of Alzheimer's disease with cholinesterase inhibitors
    L S Schneider
    Department of Psychiatry and the Behavioral Sciences and Neurology, Keck School of Medicine and the Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California 90033, USA
    Clin Geriatr Med 17:337-58. 2001
    ..This article reviews the present status of cholinesterase inhibitors for the treatment of Alzheimer's disease. It then discusses treatment approaches and current and future issues regarding efficacy and safety...
  26. ncbi request reprint Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA
    Am J Geriatr Psychiatry 14:191-210. 2006
    ..Several clinical trials have not shown efficacy, and there have been concerns about adverse events. The objective of this study was to assess the evidence for efficacy and adverse events of atypicals for people with dementia...
  27. ncbi request reprint A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    Curr Alzheimer Res 2:541-51. 2005
    ..Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results...
  28. pmc Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials
    Lon S Schneider
    Departments of Psychiatry and Neurology, Keck School of Medicine, University of Southern California, 1510 San Pablo Street, Los Angeles, CA 90033, USA
    Alzheimer Dis Assoc Disord 23:260-7. 2009
    ....
  29. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  30. ncbi request reprint Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT)
    L S Fox
    Department of Psychology, University of Southern California, Los Angeles, USA
    Int J Geriatr Psychiatry 13:544-9. 1998
    ..Our results suggest that list learning and recall seem to be lost relatively early in AD. Measures of list recall like the CVLT may not be useful in tracking severity of cognitive impairment over time...
  31. pmc Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
    L S Schneider
    Departments of Psychiatry and the Behavioral Sciences, and Neurology, Keck School of Medicine, Leonard Davis School of Gerontology of the University of Southern California, Los Angeles, CA, USA
    J Intern Med 275:251-83. 2014
    ..Only drugs that affect an aspect of cholinergic function have shown consistent, but modest, clinical effects in late-phase trials. There is opportunity for substantial improvements in drug discovery and clinical development methods...
  32. ncbi request reprint Can estrogens prevent neurodegeneration?
    L S Schneider
    University of Southern California, School of Medicine, Los Angeles, USA
    Drugs Aging 11:87-95. 1997
    ..Although basic research will progress, there is currently sufficient knowledge to promote active clinical research on the possible disease-modifying or neuroprotective effects of estrogens in the elderly...
  33. ncbi request reprint Overview of clinical trials of hydergine in dementia
    L S Schneider
    Department of Psychiatry, University of Southern California School of Medicine, Los Angeles
    Arch Neurol 51:787-98. 1994
    ..To assess the overall effect of Hydergine (a combination drug called ergoloid mesylates) on patients with possible dementia and to investigate potential moderators of an effect...
  34. ncbi request reprint Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients?: A longitudinal analysis
    C G Ippen
    Department of Psychology, University of Southern California, Los Angeles, USA
    Am J Geriatr Psychiatry 7:321-30. 1999
    ..Therefore, informant-based measures appear to be reliable and valid methods of identifying cognitive change in AD patients...
  35. ncbi request reprint Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
    Harish Kavirajan
    Department of General Internal Medicine, Division of Health Services Research, Veterans Affairs Greater Los Angeles Health Care System, CA, USA
    Lancet Neurol 6:782-92. 2007
    ..A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular dementia...
  36. ncbi request reprint Assessing outcomes in Alzheimer disease
    L S Schneider
    University of Southern California, Keck School of Medicine, Los Angeles 90033, USA
    Alzheimer Dis Assoc Disord 15:S8-18. 2001
    ..Each instrument has its own advantages and disadvantages. However, the instruments used need to be selected carefully to provide credible and informative outcome data...
  37. ncbi request reprint Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial
    Jacobo Mintzer
    Department of Psychiatry and Behavioral Sciences, VA Medical Center, Medical University of South Carolina, Charleston, 29406, USA
    Am J Geriatr Psychiatry 14:280-91. 2006
    ..The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD)...
  38. ncbi request reprint Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease
    L S Schneider
    Department of Psychiatry, School of Medicine, Los Angeles, California, USA
    Ann N Y Acad Sci 826:317-22. 1997
    ..Furthermore, among women on ERT receiving tacrine, there tended to be greater improvement relative to placebo among those without an APOE-epsilon 4 allele. Randomized trials are needed...
  39. ncbi request reprint Psychometric comparison of standard and computerized administration of the Alzheimer’s Disease Assessment Scale: Cognitive Subscale (ADASCog)
    J P O'Halloran
    NeuroComp Systems, Inc, Irvine, CA, USA
    Curr Alzheimer Res 8:323-8. 2011
    ..The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject...
  40. ncbi request reprint Pharmacologic therapy for behavioral symptoms of Alzheimer's disease
    P N Tariot
    Department of Psychiatry, University of Rochester Medical Center and Monroe Community Hospital, Rochester, New York, USA
    Clin Geriatr Med 17:359-76. 2001
    ..A rational approach typically hinges on matching the most dominant behavioral target symptoms to the most relevant medication class, the key information of which is summarized...
  41. pmc Sertraline for the treatment of depression in Alzheimer disease
    Paul B Rosenberg
    Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Geriatr Psychiatry 18:136-45. 2010
    ..The authors conducted a multicenter, randomized, placebo-controlled trial titled "Depression in Alzheimer's Disease-2" to assess the efficacy and tolerability of sertraline for depression in AD...
  42. ncbi request reprint Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease?
    Carolee J Winstein
    University of Southern California, Los Angeles, CA 90089 9006, USA
    Curr Alzheimer Res 4:273-6. 2007
    ..When the data were examined for coincidental changes in the two outcome measures together they are suggestive of a benefit from donepezil treatment for non-declarative and declarative processes...
  43. ncbi request reprint Psychosis of Alzheimer disease: validity of the construct and response to risperidone
    Lon S Schneider
    University of Southern California, Keck School of Medicine, Department of Psychiatry, Los Angeles, CA 90033, USA
    Am J Geriatr Psychiatry 11:414-25. 2003
    ..The authors evaluated the efficacy of risperidone in reducing psychotic and aggressive symptoms in a subgroup of patients who fulfilled operationalized criteria for psychosis of dementia...
  44. ncbi request reprint Errors in ADAS-cog administration and scoring may undermine clinical trials results
    K Schafer
    University of Southern California, San Diego, USA
    Curr Alzheimer Res 8:373-6. 2011
    ..Although errors in administration and scoring have been suggested as factors masking accurate estimates and potential effects of treatments, there have been few formal examinations of errors with the ADAS-cog...
  45. ncbi request reprint Estrogen replacement therapy and antidepressant response to sertraline in older depressed women
    L S Schneider
    Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Geriatr Psychiatry 9:393-9. 2001
    ..The results provide preliminary evidence that ERT use (without progesterone) in older depressed women may augment the antidepressant response to sertraline in terms of quality of life and general improvement...
  46. doi request reprint Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Int J Geriatr Psychiatry 24:539-44. 2009
    ..Our aim was to determine if anxiety predicts antidepressant response in previously identified placebo-controlled trials of second generation antidepressants for late-life depression...
  47. ncbi request reprint Efficacy of controlled-release paroxetine in the treatment of late-life depression
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
    J Clin Psychiatry 64:1065-74. 2003
    ..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition...
  48. ncbi request reprint Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine
    L S Schneider
    Department of Psychiatry and the Behavioral Sciences, University of Southern California School of Medicine, Los Angeles
    J Geriatr Psychiatry Neurol 2:109-12. 1989
    ..Although both carbamazepine and trazodone have been advocated for the control of aggression in organically impaired patients, they were not equally effective in this case...
  49. ncbi request reprint Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses
    Stephen J Bartels
    Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
    Psychiatr Clin North Am 26:971-90, x-xi. 2003
    ..Cautions and limitations regarding the reliance on randomized, controlled trials, meta-analyses, and systematic reviews also are presented...
  50. ncbi request reprint Evidence-based practices in geriatric mental health care
    Stephen J Bartels
    Department of Psychiatry, Dartmouth Medical School, Hannover, New Hampshire, USA
    Psychiatr Serv 53:1419-31. 2002
    ..The anticipated growth in the population of older persons with mental disorders underscores the need for a strategy to facilitate the systematic and effective implementation of evidence-based practices in geriatric mental health care...
  51. ncbi request reprint A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease
    Debomoy K Lahiri
    Department of Psychiatry and Neurology, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202 4887, USA
    Curr Drug Targets 4:97-112. 2003
    ..All these current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the AD brain in order to effectively diagnose and prevent their occurrence...
  52. doi request reprint Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence
    J Craig Nelson
    Department of Psychiatry, University of California San Francisco, CA, USA
    Am J Geriatr Psychiatry 16:558-67. 2008
    ..This systematic review and meta-analysis was undertaken to assess the evidence for efficacy of second-generation antidepressants in late-life major depression...
  53. ncbi request reprint National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics
    M Saleem Ismail
    University of Rochester Medical Center, Program in Neurobehavioral Therapeutics, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA
    Curr Alzheimer Res 4:325-35. 2007
    ..With the increasing prevalence of AD, clinicians and health care planners should look into future needs of those AD sufferers who are residing in community...
  54. ncbi request reprint Delay in nursing home placement with donepezil
    Lon S Schneider
    J Am Geriatr Soc 52:1024-6; author reply 1026-7. 2004
  55. ncbi request reprint Choosing treatment for Alzheimer's patients and their caregivers
    Lon S Schneider
    Geriatrics 58:3-18, 23; quiz 19-22. 2003
  56. ncbi request reprint The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?
    Lon S Schneider
    Int J Geriatr Psychiatry 21:9-13. 2006
  57. ncbi request reprint Cholinesterase inhibitors for Alzheimer disease
    Lon S Schneider
    JAMA 289:2359-60; author reply 2360-1. 2003
  58. ncbi request reprint Increasing ethnic minority participation in Alzheimer disease research
    Jason T Olin
    Division of Service and Intervention Research, National Institute of Mental Health, Bethesda, Maryland 20892 9635, USA
    Alzheimer Dis Assoc Disord 16:S82-5. 2002
    ..Fundamentally, researchers should consider that these strategies apply to all potential research participants, and not simply to traditionally underserved racial/ethnic populations...
  59. ncbi request reprint Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease
    Rochelle E Tractenberg
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California, San Diego 92093 0949, USA
    J Neuropsychiatry Clin Neurosci 14:303-10. 2002
    ..The ratio of expected to observed emergence provides an intuitively appealing quantification of treatment efficacy and can be used with any instrument that uses categorical or frequency ratings...
  60. ncbi request reprint Estrogen and dementia: insights from the Women's Health Initiative Memory Study
    Lon S Schneider
    JAMA 291:3005-7. 2004
  61. ncbi request reprint Recognizing and responding to atypical antipsychotic side effects
    Jeanne M Jackson-Siegal
    J Am Med Dir Assoc 5:H7-10. 2004
  62. doi request reprint Sex, race, and smoking impact olanzapine exposure
    Kristin L Bigos
    Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA
    J Clin Pharmacol 48:157-65. 2008
    ..0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine...
  63. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  64. ncbi request reprint Mild cognitive impairment
    Lon S Schneider
    Am J Geriatr Psychiatry 13:629-32. 2005
  65. ncbi request reprint Design of Depression in Alzheimer's Disease Study-2
    Barbara K Martin
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Am J Geriatr Psychiatry 14:920-30. 2006
    ....
  66. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:125-8. 2002
    ....
  67. ncbi request reprint Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:129-41. 2002
    ..Further research is needed to better define core symptoms, clinical course, and efficacy of treatments...
  68. ncbi request reprint The increasing power of placebos in trials of antidepressants
    Lon S Schneider
    JAMA 288:450. 2002
  69. ncbi request reprint Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'
    Paul B Rosenberg
    Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Int J Geriatr Psychiatry 20:119-27. 2005
    ..Criteria for the diagnosis of dAD have been proposed previously...
  70. ncbi request reprint American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition
    Peter V Rabins
    Am J Psychiatry 164:5-56. 2007
  71. ncbi request reprint Open-label extension studies and misinformation
    Lon S Schneider
    Arch Neurol 63:1036; author reply 1036-7. 2006
  72. ncbi request reprint Symptoms of late-life depression: frequency and change during treatment
    J Craig Nelson
    Dept of Psychiatry, University of California at San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
    Am J Geriatr Psychiatry 13:520-6. 2005
    ....
  73. pmc A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium
    Zaven S Khachaturian
    Alzheimers Dement 4:156-63. 2008

Research Grants2

  1. Depression in Alzheimer's Disease Study 2 (DIADS-2)
    Lon Schneider; Fiscal Year: 2007
    ..The predictive validity of defining depression in AD using a symptom scale or each of these syndromes will be assessed longitudinally against the various study outcomes, and against efficacy of response to antidepressant treatment. ..
  2. Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated
    Lon S Schneider; Fiscal Year: 2010
    ..We will also conduct a pilot analysis to determine the efficacy of PhytoSERMs to significantly reduce hot flashes. ..